TPTF invested in Zymergen, the world’s first molecular manufacturing technology company, in Series C funding of over $400 million led by returning investor SoftBank Vision Fund. The round also welcomes new investors Goldman Sachs and Hanwha Asset Management, as well as returning investors, DCVC (Data Collective), True Ventures, Two Sigma Ventures, DFJ and Innovation Endeavors. Zymergen’s Series C funding validates the company’s progress and the significant market opportunity for molecular technology, the new technological field pioneered by the company. The infusion of capital will accelerate Zymergen’s growth, enabling the company to double the capacity of its platform to meet the needs of its growing global client roster. The company will also invest in enhancing its platform, increasing the speed and predictability with which it can program and optimize biology for specific traits. Finally, Zymergen will begin commercializing products from its proprietary portfolio, including several with transformative impacts on global quality of life and population health. This combination of commercial success and continued platform innovation will catalyze industrial progress across agriculture, chemicals and materials, pharmaceuticals, and more.